Merck & Co., Inc. (MRK) BofA Securities 2025 Healthcare Conference (Transcript)

Company Overview - Merck & Co., Inc. is represented by key executives including Jannie Oosthuizen, President of U.S. Human Health, who has been in this role since 2022 and has a background in global marketing for oncology [2] - Doctor Marjorie Green serves as Senior Vice President and Head of Oncology Clinical Development, having joined Merck in 2023 from Cision [3] - Peter Dannenbaum is the Senior Vice President of Investor Relations, with the company since 2017 [3] Conference Insights - The conference included discussions on various policy questions, particularly focusing on the Most Favored Nation (MFN) policy, which is currently a significant topic of concern for the company [4] - The company is dedicating considerable internal resources to understand the implications of current policies and potential changes in the healthcare landscape [4]